Paul Phillip Rogers

US Patent:

8420784, Apr 16, 2013

Filed:

May 27, 2009

Appl. No.:

12/994789

Inventors:

Shinichiro Kato - Tokyo, JP
Rachel Soloff Nugent - La Jolla CA, US
Tomoyuki Tahara - Tokyo, JP
Paul Rogers - La Jolla CA, US
Aihua Song - La Jolla CA, US

Assignee:

Kyowa Hakko Kirin Co., Ltd. - Tokyo

International Classification:

A61K 39/395
C07K 16/28
C12P 21/08
G01N 33/53

US Classification:

5303871, 5303881, 5303891, 435 72, 4241391, 4241441

Abstract:

The invention relates to IL-1O Receptor alpha (IL-1ORα) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IORα) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1ORα) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1ORα) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1ORα) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1ORα) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization.

US Patent:

20030153073, Aug 14, 2003

Filed:

Nov 7, 2002

Appl. No.:

10/291809

Inventors:

Paul Rogers - San Diego CA, US
Toshifumi Mikayama - Nagareyama-shi, JP

International Classification:

C12N005/08
A61K045/00

US Classification:

435/372000, 424/093700

Abstract:

Methods for expanding T cells (e.g., V24V11 human NKT cells ) in vitro by repeated culturing in the presence of an antigen (e.g., glycosphingolipid), antigen presenting cells, and a cell survival factor are provided. A population of NKT cells (V24 11) can be expanded more than 1 million-fold in 5 weeks and more than 1 billion-fold in 10 weeks.